Literature DB >> 8445031

Gonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid müllerian-inhibiting substance and androgen content.

D B Seifer1, D T MacLaughlin, A S Penzias, H R Behrman, L Asmundson, P K Donahoe, R V Haning, S D Flynn.   

Abstract

We have previously shown that the proliferative index (PI), as determined by flow cytometry of luteinized granulosa cells obtained at oocyte retrieval, is greater in ovulation induction regimens which include the GnRH analog (GnRH-a) leuprolide acetate than those using human menopausal gonadotropin (hMG) only. Specific growth factors or intrafollicular hormones may contribute to this leuprolide acetate-induced difference in cell cycle kinetics. We examined whether differences in the PI of these granulosa cells are associated with the alterations of follicular fluid content of Mullerian-inhibiting substance (MIS) and other intrafollicular hormones including FSH, estradiol, progesterone, androstenedione, and testosterone. The control group consisted of follicular fluid obtained from 18 follicles from 4 women receiving hMG alone. The GnRH-a treated group consisted of follicular fluids obtained from 55 follicles aspirated from 18 women receiving GnRH-a in addition to hMG. One-way analysis of variance using log-transformed data and expressed as geometric means with 95% confidence intervals, demonstrated that the follicles from the control group had a significant 14-fold higher concentration of 2.46 ng/mL MIS, 95% CI (1.8-4.8) vs. 0.18 ng/mL, 95% CI (0.13-0.24) P < 0.0005, a 3-fold higher concentration of 17.55 nmol/L androstenedione, 95% CI (14.6-20.9) vs. 5.76 nmol/L, 95% CI (3.1-10.5) P < 0.02, and a 1.5-fold higher concentration of 29.43 nmol/L testosterone 95% CI (22.5-38.14) vs. 19.3 nmol/L, 95% of CI (11.1-33.9) P < 0.01 than GnRH-a treated follicles, although the PI value in controls was half that of the GnRH-a group. These data demonstrate that GnRH-a induced differences in granulosa cell cycle kinetics are associated with alterations of MIS and androgen intrafollicular fluid content and suggest that MIS may be a mitotic inhibitor of human granulosa cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8445031     DOI: 10.1210/jcem.76.3.8445031

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Interrelation of androgen receptor and miR-30a and miR-30a function in ER-, PR-, AR+ MDA-MB-453 breast cancer cells.

Authors:  Shuhua Lyu; Han Liu; Xia Liu; Shan Liu; Yahong Wang; Qi Yu; Yun Niu
Journal:  Oncol Lett       Date:  2017-08-21       Impact factor: 2.967

2.  AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy.

Authors:  Motohiro Kano; Amanda E Sosulski; LiHua Zhang; Hatice D Saatcioglu; Dan Wang; Nicholas Nagykery; Mary E Sabatini; Guangping Gao; Patricia K Donahoe; David Pépin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

3.  Rosiglitazone suppresses glioma cell growth and cell cycle by blocking the transforming growth factor-beta mediated pathway.

Authors:  Peng Wang; Jinpu Yu; Qiang Yin; Wenliang Li; Xiubao Ren; Xishan Hao
Journal:  Neurochem Res       Date:  2012-06-16       Impact factor: 3.996

Review 4.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

Review 5.  Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine.

Authors:  Vitaly A Kushnir; David B Seifer; David H Barad; Aritro Sen; Norbert Gleicher
Journal:  J Assist Reprod Genet       Date:  2017-06-22       Impact factor: 3.412

6.  Correlation of serum anti-Mullerian hormone with hormonal and environmental parameters in Brazilian climacteric women.

Authors:  Thiago Magalhães Gouvea; Laura Alves Cota E Souza; Angélica Alves Lima
Journal:  Sci Rep       Date:  2022-07-14       Impact factor: 4.996

7.  Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle-stimulating hormone (FSH) in normoandrogenic ovulatory women undergoing gonadotropin releasing-hormone analog/recombinant human FSH therapy for in vitro fertilization and embryo transfer.

Authors:  Daniel A Dumesic; Timothy G Lesnick; Jacques P Stassart; G David Ball; Ashley Wong; David H Abbott
Journal:  Fertil Steril       Date:  2009-07       Impact factor: 7.329

8.  Follicular fluid anti-Müllerian hormone (AMH) concentrations and outcomes of in vitro fertilization cycles with fresh embryo transfer among women at a fertility center.

Authors:  Caitlin R Sacha; Jorge E Chavarro; Paige L Williams; Jennifer Ford; LiHua Zhang; Patricia K Donahoe; Irene C Souter; Russ Hauser; David Pépin; Lidia Mínguez-Alarcón
Journal:  J Assist Reprod Genet       Date:  2020-10-06       Impact factor: 3.412

Review 9.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

10.  Effects of GnRH agonists on the expression of developmental follicular anti-mullerian hormone in varying follicular stages in cyclic mice in vivo.

Authors:  Jiliang Huang; Xiaoyan Wang; Zhiling Li; Ruowu Ma; Wanfen Xiao
Journal:  Mol Med Rep       Date:  2015-06-24       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.